Form 4: Lilly Endowment Sells Eli Lilly Shares
Statement of Changes in Beneficial Ownership
Lilly Endowment Inc. reported the sale of Eli Lilly & Co. common stock valued at approximately $13.5 million.
Summary
- Lilly Endowment Inc. has reported the sale of 13,620 shares of Eli Lilly & Co. common stock on May 6, 2026, for a weighted average price of $995.225 per share.
- An additional 2,208 shares were sold on the same date for a weighted average price of $996.183 per share.
- Following these transactions, Lilly Endowment Inc. beneficially owns 91,881,150 shares of Eli Lilly & Co. common stock.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by a major holder, although the reasons are not specified and the remaining ownership is still substantial.
Negatives
- Lilly Endowment Inc. sold a significant number of Eli Lilly & Co. shares, indicating a reduction in their direct beneficial ownership.
Future Outlook
No specific future outlook or guidance is provided in this Form 4 filing, which solely reports past transactions.
Management Comments
- The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) and (2) to this Form 4.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for significant shareholders and insiders. The sale of a substantial number of shares by a major endowment like Lilly Endowment Inc. could be interpreted by the market, though the exact reasons are not disclosed in this filing.
Stakeholder Impact
- Shareholders: The sale of a large block of shares by Lilly Endowment Inc. could potentially exert downward pressure on the stock price, depending on market interpretation and the overall trading volume.
Key Dates
| Date | Description |
|---|---|
| 05/06/2026 | Earliest transaction date and date of stock sales. |
| 05/07/2026 | Date of signature for the filing. |
Recommendation
holdThe filing reports a sale of shares by Lilly Endowment Inc., a significant holder. While this indicates a reduction in their stake, the remaining ownership is still substantial, and the reasons for the sale are not provided. Without further context on the endowment's strategy or the company's performance, a 'hold' recommendation is prudent, awaiting more information or market reaction.
Keywords
Eli Lilly, LLY, Stock Sale, Insider Trading, Beneficial Ownership, Lilly Endowment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.